212 related articles for article (PubMed ID: 18261626)
1. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy.
Siraj AK; Bavi P; Abubaker J; Jehan Z; Sultana M; Al-Dayel F; Al-Nuaim A; Alzahrani A; Ahmed M; Al-Sanea O; Uddin S; Al-Kuraya KS
J Pathol; 2007 Oct; 213(2):190-9. PubMed ID: 17703498
[TBL] [Abstract][Full Text] [Related]
3. The expression and role of serum response factor in papillary carcinoma of the thyroid.
Kim HJ; Kim KR; Park HS; Jang KY; Chung MJ; Shong M; Moon WS
Int J Oncol; 2009 Jul; 35(1):49-55. PubMed ID: 19513551
[TBL] [Abstract][Full Text] [Related]
4. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
Nasser SM; Pitman MB; Pilch BZ; Faquin WC
Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
[TBL] [Abstract][Full Text] [Related]
5. Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors.
Puskas LG; Juhasz F; Zarva A; Hackler L; Farid NR
Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(2):177-86. PubMed ID: 16171553
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical distinction of follicular thyroid adenomas and follicular carcinomas.
Bryson PC; Shores CG; Hart C; Thorne L; Patel MR; Richey L; Farag A; Zanation AM
Arch Otolaryngol Head Neck Surg; 2008 Jun; 134(6):581-6. PubMed ID: 18559722
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical characteristics of diffuse sclerosing variant of papillary carcinoma: comparison with conventional papillary carcinoma.
Koo JS; Shin E; Hong SW
APMIS; 2010 Oct; 118(10):744-52. PubMed ID: 20854468
[TBL] [Abstract][Full Text] [Related]
8. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
9. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study.
Wasenius VM; Hemmer S; Kettunen E; Knuutila S; Franssila K; Joensuu H
Clin Cancer Res; 2003 Jan; 9(1):68-75. PubMed ID: 12538453
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.
Jarzab B; Wiench M; Fujarewicz K; Simek K; Jarzab M; Oczko-Wojciechowska M; Wloch J; Czarniecka A; Chmielik E; Lange D; Pawlaczek A; Szpak S; Gubala E; Swierniak A
Cancer Res; 2005 Feb; 65(4):1587-97. PubMed ID: 15735049
[TBL] [Abstract][Full Text] [Related]
12. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms.
Mehrotra P; Okpokam A; Bouhaidar R; Johnson SJ; Wilson JA; Davies BR; Lennard TW
Histopathology; 2004 Nov; 45(5):493-500. PubMed ID: 15500653
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
14. Recent developments in the clinical application of thyroid cancer biomarkers.
Shibru D; Chung KW; Kebebew E
Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
[TBL] [Abstract][Full Text] [Related]
15. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
16. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma.
Cvejic D; Savin S; Petrovic I; Selemetjev S; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2005 Sep; 27(3):210-4. PubMed ID: 16244583
[TBL] [Abstract][Full Text] [Related]
17. Hashimoto's thyroiditis with papillary thyroid carcinoma (PTC)-like nuclear alterations express molecular markers of PTC.
Prasad ML; Huang Y; Pellegata NS; de la Chapelle A; Kloos RT
Histopathology; 2004 Jul; 45(1):39-46. PubMed ID: 15228442
[TBL] [Abstract][Full Text] [Related]
18. Galectin-3 expression in papillary thyroid carcinoma: relation to histomorphologic growth pattern, lymph node metastasis, extrathyroid invasion, and tumor size.
Cvejic DS; Savin SB; Petrovic IM; Paunovic IR; Tatic SB; Havelka MJ
Head Neck; 2005 Dec; 27(12):1049-55. PubMed ID: 16155918
[TBL] [Abstract][Full Text] [Related]
19. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of mucins 1-6 in papillary thyroid carcinoma: evidence for transformation-dependent post-translational modifications of MUC1 in situ.
Magro G; Schiappacassi M; Perissinotto D; Corsaro A; Borghese C; Belfiore A; Colombatti A; Grasso S; Botti C; Bombardieri E; Perris R
J Pathol; 2003 Jul; 200(3):357-69. PubMed ID: 12845632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]